{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=9&state=California", "query": { "state": "California", "city": "Redwood City", "page": 9 }, "page_size": 10 }, "pagination": { "page": 9, "page_size": 10, "total_count": 289, "total_pages": 29, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=10&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Redwood+City&page=8&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T13:38:38.963Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02595424", "title": "Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Neuroendocrine Carcinoma", "Intestinal Neuroendocrine Carcinoma", "Pancreatic Neuroendocrine Carcinoma" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2015-11-06", "completion_date": "2029-01-01", "has_results": true, "last_update_posted_date": "2026-11-02", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 673, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Fort Smith, Arkansas + 431 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02595424" }, { "nct_id": "NCT03033576", "title": "Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage III Cutaneous Melanoma AJCC v8", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Melanoma of Unknown Primary", "Mucosal Melanoma", "Unresectable Cutaneous Melanoma", "Unresectable Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2017-10-23", "completion_date": "2024-03-20", "has_results": true, "last_update_posted_date": "2025-01-13", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 638, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 392 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03033576" }, { "nct_id": "NCT02954874", "title": "Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Carcinoma In Situ", "Invasive Breast Carcinoma", "Stage I Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage III Breast Cancer AJCC v7", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1195, "start_date": "2017-01-18", "completion_date": "2027-08-27", "has_results": false, "last_update_posted_date": "2026-10-26", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 895, "location_summary": "Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Daphne", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954874" }, { "nct_id": "NCT03650556", "title": "Safety and Effectiveness of TactiCath™ Contact Force, Sensor Enabled™ (TactiCath SE) Catheter for Ablation of Drug Refractory, Symptomatic, Persistent Atrial Fibrillation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Persistent Atrial Fibrillation" ], "interventions": [ { "name": "TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 224, "start_date": "2018-09-28", "completion_date": "2021-01-11", "has_results": true, "last_update_posted_date": "2022-04-27", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 20, "location_summary": "Birmingham, Alabama • Jonesboro, Arkansas • Little Rock, Arkansas + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03650556" }, { "nct_id": "NCT05568472", "title": "Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Hormone Receptor-Positive Breast Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Endocrine Drug Therapy", "type": "PROCEDURE" }, { "name": "Health Education", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Symptom Specific Assessment Tool", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "BEHAVIORAL" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 565, "start_date": "2023-03-29", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 489, "location_summary": "Kingman, Arizona • Phoenix, Arizona • Antioch, California + 333 more", "locations": [ { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05568472" }, { "nct_id": "NCT01349881", "title": "S0820, Adenoma and Second Primary Prevention Trial", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "Eflornithine placebo & sulindac placebo", "type": "DRUG" }, { "name": "eflornithine & sulindac placebo", "type": "DRUG" }, { "name": "Eflornithine placebo & sulindac", "type": "DRUG" }, { "name": "Eflornithine plus sulindac", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 354, "start_date": "2013-08-23", "completion_date": "2032-02-01", "has_results": false, "last_update_posted_date": "2026-10-23", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 989, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 616 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01349881" }, { "nct_id": "NCT00140101", "title": "Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Coronary Disease", "Coronary Artery Disease", "Coronary Restenosis" ], "interventions": [ { "name": "ZoMaxx™ Drug-Eluting Coronary Stent System", "type": "DEVICE" }, { "name": "TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Abbott Medical Devices", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1099, "start_date": "2005-05", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-01-10", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 74, "location_summary": "Huntsville, Alabama • Gilbert, Arizona • La Jolla, California + 60 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Redwood City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00140101" }, { "nct_id": "NCT02104674", "title": "A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Lebrikizumab", "type": "DRUG" }, { "name": "Montelukast", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 313, "start_date": "2014-06-07", "completion_date": "2016-01-22", "has_results": true, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 38, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 30 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02104674" }, { "nct_id": "NCT00072046", "title": "Interferon Alfa-2b With or Without Bevacizumab in Treating Patients With Advanced Renal Cell Carcinoma (Kidney Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "bevacizumab", "type": "BIOLOGICAL" }, { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 732, "start_date": "2003-10", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2016-07-06", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 489, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 341 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00072046" }, { "nct_id": "NCT00489411", "title": "Duloxetine in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurotoxicity", "Pain", "Peripheral Neuropathy", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "duloxetine hydrochloride", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": null, "sex": "ALL", "summary": "25 Years and older" }, "enrollment_count": 231, "start_date": "2008-04", "completion_date": "2013-03", "has_results": true, "last_update_posted_date": "2017-04-26", "last_synced_at": "2026-11-06T13:38:38.963Z", "location_count": 475, "location_summary": "Antioch, California • Berkeley, California • Burlingame, California + 328 more", "locations": [ { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00489411" } ] }